ClinicalTrials.gg
Not yet recruitingNCT07903831Updated Oct 29, 2026

Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B

A Phase 1 interventional study of SCTA02A and Placebo in Hepatitis B, sponsored by Sinocelltech Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's title name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 1, Interventional, and Treatment

Updated Oct 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 377 studies in Hepatitis B, Chronic with a site in China — 90 open to participants now, 111 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
204th of 274
60 · median 120
Started
2026
with 27 others
Phase 1
51 of 377
17 open now
Primary completion
2027-09
later than 77 of 110 live
Registered
374th of 377
by date

Among the 377 studies in Hepatitis B, Chronic with a site in China, this one is the 204th largest by planned enrollment of the 274 interventional ones that give a count, is one of 28 that started in 2026, is one of 51 in phase 1, reaches primary completion later than 77 of the 110 other live ones, and was the 374th registered.

Hepatitis B, Chronic

898 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

90 of the 377 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

Study SCTA02A-A101 is designed to assess the safety, tolerability and pharmacokinetics of SCTA02A in healthy volunteers and participants with chronic hepatitis B virus infection. Eligible participants will receive study treatment in this phase 1 dose-escalation study. All treated patients will also undergo a safety follow-up period after last study drug administration.

Read the detailed description

SCTA02A, a hepatitis B virus neutralizing monoclonal antibody. This Phase I dose-escalation study consists of two parts: Part Ia is a single ascending dose study in healthy volunteers with 24 participants; Part Ib is a multiple ascending dose study in participants with chronic HBV infection with 36 participants, and will assess preliminary efficacy.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Chronic Hepatitis B
04

In context

Hepatitis B, Chronic Reclassified

898 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's planned enrollment of 60 is below the median of 100 across 660 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

Sinocelltech Ltd. is the lead sponsor of 82 studies on the registry; 33 are open to participants now.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers: 18 to 60 years old (inclusive)
  • Participants with chronic : 18 to 65 years old (inclusive)
  • Sex: male or female
  • Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and (BMI): 18 kg/m² ≤ BMI ≤ 28 kg/m²

Exclusion criteria

Exclusion Criteria:

  • or intolerance to immunoglobulin, the active ingredient or of SCTA02A; Any history of severe allergic reactions
  • History of active infection or fever within 14 days prior to enrollment
  • Presence of primary disease of major organs
  • Diagnosis of disease
  • Use of any prescription drugs, over-the-counter drugs, or herbal medicines within 7 days prior to dosing
  • Participation in another clinical trial of drug or medical device within 3 months prior to screening
  • Vaccination within 30 days prior to screening
  • History of prior
  • Major surgical procedure within 3 months prior to screening
  • Weekly alcohol consumption exceeding 14 standard units within 3 months prior to screening
  • History of drug or substance abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SCTA02A

    Biological: SCTA02A

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalSCTA02A

    SCTA02A, an investigational monoclonal antibody.

  • BiologicalPlacebo

    Placebo

07

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-related adverse events (TRAEs) after administration.Maximum tolerated dose(MTD)

    Time frame: up to 16 weeks

  2. HBsAg change from baseline (Ib)

    Time frame: up to 16 weeks

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: up to 16 weeks

  2. Time to Reach Maximum Plasma Concentration (Tmax)

    Time frame: up to 16 weeks

  3. Apparent Terminal Elimination Half-life (t1/2)

    Time frame: up to 16 weeks

  4. Immunogenicity: ADA

    Time frame: up to 16 weeks

  5. Incidence and severity of adverse events (AE) , serious adverse events (SAE) and adverse events of special interest (AESI)

    Time frame: up to 16 weeks

  6. HBV DNA change from baseline (Ib)

    Time frame: up to 16 weeks

  7. proportion of HBV DNA < LLOQ (Ib)

    Time frame: up to 16 weeks

  8. ALT change from baseline (Ib)

    Time frame: up to 16 weeks

08

Study locations

1 site
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.

Of 74 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 11 months is below that.

Counting every sponsor, half of 82 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Oct 29, 2026
StartEst.
Oct 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07903831
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Oct 29, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Lili Ma
Contact
lili_ma@sinocelltech.com
+86 10-58628288

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion